Brazilian Medicine Angioplasty or Surgery Study (MASS) finds little difference between angina therapies:
This article was originally published in Clinica
Bypass surgery patients were less likely to need revascularisation than those treated by PTCA or medication in the Brazilian Medicine Angioplasty or Surgery Study (MASS). None of the bypass patients needed revascularisation during a three-year follow-up period. All three strategies eventually eradicating limiting-angina but bypass and angioplasty gave greater initial relief and better treadmill test scores. There was no difference in mortality or infarction rates, says Dr Whady Hueb, writing in the Journal of the American College of Cardiology (December).
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.